1 reports of this reaction
6.3% of all FERRUM PHOSPHORICUM reports
#9 most reported adverse reaction
OCULAR HYPERAEMIA is the #9 most commonly reported adverse reaction for FERRUM PHOSPHORICUM, manufactured by Energique, Inc.. There are 1 FDA adverse event reports linking FERRUM PHOSPHORICUM to OCULAR HYPERAEMIA. This represents approximately 6.3% of all 16 adverse event reports for this drug.
Patients taking FERRUM PHOSPHORICUM who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among FERRUM PHOSPHORICUM users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for FERRUM PHOSPHORICUM:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 1 FDA reports for FERRUM PHOSPHORICUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 6.3% of all adverse event reports for FERRUM PHOSPHORICUM, making it a notable side effect.
If you experience ocular hyperaemia while taking FERRUM PHOSPHORICUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.